Advances in Entomology
Vol.04 No.05(2016), Article ID:70152,11 pages
10.4236/ae.2016.45026

Introduction, Sign, Symptoms, Prevention and Management of Lyme Disease Caused by Borrelia burgdorferi Channeled through Ixodes Ticks as Vector. A Review

Fakhra Tabbasam, Muhammad Faheem Malik, Usman Asghar, Kamaran Saeed Paracha, Takhmina Nazir

University of Gujrat, Ghakkhar, Pakistan

Copyright © 2016 by authors and Scientific Research Publishing Inc.

This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).

http://creativecommons.org/licenses/by/4.0/

Received: June 25, 2016; Accepted: August 26, 2016; Published: August 29, 2016

ABSTRACT

God has created many miraculous creature; ticks are one of them. Borrelia burgdorferi is a bacterium that lives into the gut of ticks. When such ticks feed upon the blood of Ticks and other livestock, bacteria are transferred into their blood stream of these hosts. A disease is caused into human beings if such infected tick bites humans that are called as Lyme disease. This review will help to have a keen study on the cause, sign, symptoms, prevention and management of this disease.

Keywords:

Borrelia burgdorferi, Livestocks

1. Introduction

Lyme disease is caused by ticks. There are about 800 different species of ticks. They have two families family Argasidae that have about 160 species. Second family is of hard ticks that has 650 species. Ticks and ticks are considered as close relatives of mites regarding their parasitic life style. Ticks have complex life style. They need more than one type of hosts to spend their life; for example American Dog ticks is a three host ticks. Ticks can live alive for years in the absence of their host so it is a facultative host [1] .

Ticks are very small in size; victim cannot identify easily where ticks have bitten. Typically when ticks bite redness of the skin is first symptom. This redness expands to form an annular lesion having red borders. About 35 percent of patients in USA have lesions with clear central part that maybe necrotic or vesicular [2] [3] .

The life circle of Borrelia burgdorferi is transferred via Ticks. Four developmental stages are occurred under the life of Ticks. Larvae are infected with bacteria when a larva feeds upon mice. After molting larvae transferred into nymphs. Ticks spread infection to humans via some small animals like white tailed mouse, deer, some birds all act as reservoirs for B. burgdorferi.

Most infection of LD is because of the biting of Nymph because Nymph has poppy seed size and it is not visible by the victim. The whole life circle of B. burgdorferi needed 36 to 48 hours for attachment. Circle in this way the life circle is completed [4] [5] .

Development of ticks started when the eggs are hatched into six legged Larvae. Nymphs and adults are also eight legged. There are two groups of ticks i.e. soft and hard ticks. Soft ticks have seven nymph instars while hard ticks have one nymph instars [6] .

Ticks have two chance to get infect with Borrelia burgdorferi i.e. during larval and nymph stages. So humans are at the peak of risk during spring and summer season, because ticks are active at that season [7] - [9] .

The alternative name of Lyme disease is as Lyme borreliosis. At least three stages are present in the course of Lyme disease (1) acute (2) early disseminated (3) chronic [10] .

Lyme disease was first time observed in Europe; it gradually prevails into American countries rapidly. It is a disease that is spread through Bacteria with the help of a vector i.e. Tick.

Humans are affected badly because it adversely affects the central nervous system, skin, joints of legs and allergy on whole body is mostly observed. If cutaneous infection is encountered it is referred to as erythema migrans [11] .

If cutaneous infection resulted, it is referred to as erythema migrans. Lyme disease is caused by a bacteria Borrelia burgdorferi. It has corkscrew shape and is a member of spirochetes [12] .

After the study at laboratory level it is predicted that about forty to forty eight hours are required for the infection [13] .

2. Disease Sign and Symptoms

Lyme disease is considered as asymptomatic disease. The culturing of B. burgdorferi is a tool in expanding the knowledge and understanding about the sub species [14] - [16] . Symptoms appeared within one month after the insect bite. Tick feed for24 to 36 hours on the blood of victim to transfer the bacterial agent. During this period bacteria transfer from the gut of tick into the saliva of tick and finallyit reaches into the body of host. So bacteria use Tick as vector. If ticks bite for short time it does not causes infection [17] .

The first symptom of disease is the appearance of redness on skin that may call bull’s eye rash or erythematic migrans present on infected individuals. About seventy to eighty percent of infected individuals developed erythema migrans only a slight difference in the size and shape [18] .

The most common sign and symptoms includes skin-rash at which ticks are attached. Infection spread from centre to outward converting the skin into dark red [19] .

The most observable symptoms include fever, hardness of neck, flu, headache, and headache, inflammation of muscles and joints and fatigue. To nip the evil in bud is the solution of early stage symptoms [20] .

Later stage symptoms of LD may take weeks to years to become prominent. If untreated, late stage symptoms are encountered that affect heart, joints, and CNS also [21] .

About sixty percent of patients are affected with arthritis; if treatment is not started on early basis. This may lead to chronic infection. Nervous system is also adversely affected. Lyme disease affects the nervous system in second stage. The most probable symptoms includes hardness and stiffnes of the neck region, waves of pain in head, meningitis, peripheral rediculopathy at peripheral region, fear from light and long term vomiting shows meningeal involvement [21] - [23] . Heart beat slows down because of this disorder that leads to senselessness of the patient [22] .

The disease is spread through the biting of an infected black legged tick (Ixodes scapularis) and it can bite to an individual of any age. Tick itself is infected with bacteria when it bites a man it sucks blood and ultimately transfers bacteria into the body of human. Within three to 33 days symptoms may appear that includes allergy and neural disorder and joints problem. However it is not transmitted under touching, kissing and intercourse [23] .

Halprein et al. (2011) described the symptoms of LD in case of brain. He called the brain symptoms as Brain Frog. Because of this, patients feel fatigue tiredness and mentally absence for most of their time. The infection of Brain because of Borrelia burgdorferi is referred as meningitis [24] [25] .

In meningitis there is risk of getting benign tumor. LD also affects CSF, spinal cord and often leads to encephalomyelitis. Fortunately this disorder can be cured by taking antibiotics regularly [26] .

The other constitutional sign and symptoms includes arthralgias, myalgias, lymphadenopathy and hectic fatigue are more noticeable symptoms. About ten percent of victims do not show the redness of skin [27] .

Patients may also show the symptoms of high temperature, headache, leucopenia, lymphopenia, myalgias, increased liver enzyme content and thrombocytopenia [28] .

Variable symptoms that may appear in patients include loss of memory, muscles fatigue, depression, headache, irritability and problem in sleeping [29] . Most of the symptoms are the chronic Lyme disease [30] .

Depression, anxiety, loss of temperament and rage are the symptoms of acute and chronic Lyme disease [31] .

Initial symptoms include bulls eye i.e. erythema migrans, but about fifty one percent of patients do not show rashes [32] . Rashes may be flat in shape [33] . Rashes are just as are formed by the biting of spider and ringworm [34] .

3. Medication and Prevention of Disease

Diagnosis is important before medication. Different tests are used under different circumstances. ELISA test is used to identify the increased Borrelia antibiotics [35] .

Diagnosis and treatment is different in both International Lyme and Associated Disease Society (ILDS) and IDSA [36] [37] .

These fluctuations predict that doctors do not use constant method for diagnosis and cure. About more than four weeks are required to treat LD [38] - [47] .

Protein Immunoblots test, western Blot tests, Melisa test, LTT, Elispot, test of CSF, PCR method, Dark field microscopy, FFM are the most probable test used for diagnosis [48] .

For patients suffering with Erythema migrans are suggested to take Doxycycline (100 mg/per 2 day) [49] .

Serology testing is often used for the diagnosis of LD, but it shows some drawback because it does not help to distinguish between active and inactive infection and patient shows sero-positive for many years even antibiotics are administrated regularly [50] [51] .

Gary et al. gave guidelines for the management of Lyme disease. Prevention is better than cure, by focusing this formula he concluded that special care must be given to diseased person or those are at risk of getting disease [52] - [55] .

The most effective tools that are used for the prevention of disease includes 1) prevent our selves from the exposure of ticks as much as possible; 2) avoid to travel in a brushy areas; 3) use of light coloure dresses that help to detect the sitting of Ticks immediately; 4) use of full sleeved shirt; 5) for the sake of foot use top socks; 6) use of insect repellents regularly; 7) monitoring the ticks visit on daily basis; 8) if ticks is attached on one’s body remove it abruptly. We should aware of the fact that Lyme disease is vector pinched disease. We can prevent us from the exposure of ticks but unfortunately, if one gets ticks bite, one should have clinical checkup and if test is positive he/she should have its complete treatment until the end of disease [56] .

Gary et al. recommended Amoxicillin, Doxycycline, Cefuroxime axetill, ceftriaxone, cefotaxime and penicillin G. the concentration of all these medicines is different for both adults and children [57] .

According to a survey, if one gets the symptoms of LD one should experience through the whole course of antibiotics tablets, liquids and capsules. Duration of intake varied from person to person. If health-condition is better than before; it shows that all bacteria have been killed. If health is not getting normalize one should refer to some specialist [58] .

Biological control can be used for the prevention of LD for example entomopathogenic fungi is use that causes the destruction of Ticks [59] .

We should reduce the number of deer in an area because deer are the blood meal of Ticks. Antimicrobial Prophylaxis is used in Europe but prophylactic is under controversial issue [60] .

According to the survey by the centers for disease control and prevention about 3 lac people are suffering with LD in which 25 percent are children. Such a high rate of patients is because of carelessness, late diagnosis, wrong testing, wrong medication etc. [61] .

One of the most accurate tests for the diagnosis of LD is Human Tissue Biopsies test. It is helpful in determining the persistence of Lyme bacteria [62] .

4. Treatment of LD

Antimicrobial therapy is used for the treatment of LD. If redness on skin, isolated facial nerve palsy and mild cardiac disease occur, antibiotics are taken orally for 14 - 21 days. If the symptoms of meningitis and radiculoneuritis are noticed, antibiotics are administrated intravenously for 10 - 28 days. If patients are facing with first stage block with PR interval of ≥0.3, second or third stage artrioventricular block such patients must be referred to hospital for complete monitoring of heart. The therapy used for neuroborreliosis is the uptake of antibiotics intravenously for 14 - 28 days. For Arthritis, oral regimen is used if results are not satisfactory they should take regimen intravenously for 14 - 28 days. If patients do not show improvement he may have Antibiotic-refractory Lyme arthritis [11] [18] .

An OspA-based vaccine was used to prevent LD, but it was banned because of poor sales and theoretic concerns about triggering autoimmune arthritis [63] [64] .

About 65% - 80% of the disorder can be eradicated by using intravenous ceftriaxone for two to four weeks [65] .

For the treatment of LD steroid therapy was used but it is not recommended now because of bad outcomes and immune suppression [66] .

If antibiotics treatment does not give satisfactory results for the joints of knee surgical synovectomy is recommended [66] .

Other therapies that are used against LD are symptomatic therapy. It is an anti-inflammatory treatment that is often used when victim is failed to response to antibiotics [67] .

Other therapy is the hyperbaric oxygen therapy is under studies but it’s not used for regular concerns [68] .

Chronic Lyme disease is an intermingled term that can be described for different populations of patients included early, late Lyme disease and no evidence of Lyme disease [69] - [71] .

Ixodes ticks also causes co-infection for humans causing HGA (human granulocytic anaplasmosis). Concluding, laboratories at commercial level offers non-validated Lyme diagnostic test is not appreciated now a day’s [72] .

Recently it has been observed that when the ticks bite humans the Auto-reactive T cells are activated because of tremendous inflammation. It is the first response of immune system locating in our body for defense that triggers to inhibit the infection [73] - [75] .

5. Conclusion

It is a highly infectious disease. Advancement in research leads to the better diagnosis and describes the main feature of disease, isolation and culturing of germ. In upcoming era it is expected that the interaction between bacteria, vector and Host will be understood. This collection of words should develop new insights that will help in the better diagnosis, treatment and management of disease.

6. Recommendation

Prevention from the exposure of Ticks must be first priority. Nip the disease in the bud if infection occurs.

Acknowledgements

This review was guided by my supervisor Dr. Mubshar.

Cite this paper

Tabbasam, F., Malik, M.F., Asghar, U., Paracha, K.S. and Nazir, T. (2016) Introduction, Sign, Symptoms, Prevention and Management of Lyme Disease Caused by Borrelia burgdorferi Chan- neled through Ixodes Ticks as Vector. A Review. Advances in Entomology, 4, 249- 259. http://dx.doi.org/10.4236/ae.2016.45026

References

  1. 1. Iliopoulou, B.P., Alroy, J. and Huber, B.T. (2007) CD28 Deficiency Exacerbates Joint Inflammation upon Borrelia burgdorferi Infection, Resulting in the Development of Chronic Lyme Arthritis. The Journal of Immunology, 179, 8076-8082. http://dx.doi.org/10.4049/jimmunol.179.12.8076

  2. 2. Codolo, G., Amedei, A., Steere, A.C., et al. (2008) Borrelia burgdorferi NapA-Driven Th17 Cell Inflammation in Lyme Arthritis. Arthritis & Rheumatology, 58, 3609-3617. http://dx.doi.org/10.1002/art.23972

  3. 3. Ones, K.L., McHugh, G.A., Glickstein, L.J. and Steere, A.C. (2009) Analysis of Borrelia burgdorferi Genotypes in Patients with Lyme Arthritis: High Frequency of Ribosomal RNA Intergenic Spacer Type 1 Strains in Antibiotic-Refractory Arthritis. Arthritis & Rheumatology, 60, 2174-2182. http://dx.doi.org/10.1002/art.24812

  4. 4. Marques, A., Brown, M.R. and Fleisher, T.A. (2009) Natural Killer Cell Counts Are Not Different between Patients with Post-Lyme Disease Syndrome and Controls. Clinical and Vaccine Immunology, 16, 1249-1250. http://dx.doi.org/10.1128/CVI.00167-09

  5. 5. McHugh.LA McHugh (2008) Effect of Electronic Laboratory Reporting on the Burden of Lyme Disease Surveillance—New Jersey, 2001-2006. Morbidity and Mortality Weekly Report, 57, 42-45.

  6. 6. Marques, A. (2008) Chronic Lyme Disease: A Review. Infectious Disease Clinics of North America, 22, 341-360. http://dx.doi.org/10.1016/j.idc.2007.12.011

  7. 7. Feder Jr., H.M., Johnson, B.J., O’Connell, S., et al. (2007) A Critical Appraisal of “Chronic Lyme Disease”. The New England Journal of Medicine, 357, 1422-1430.

  8. 8. Ledue, T.B., Collins, M.F., Young, J. and Schriefer, M.E. (2008) Evaluation of the Recombinant VlsE-Based Liaison Chemiluminescence Immunoassay for Detection of Borrelia burgdorferi and Diagnosis of Lyme Disease. Clinical and Vaccine Immunology, 15, 1796- 1804. http://dx.doi.org/10.1128/CVI.00195-08

  9. 9. Wormser, G.P., Dattwyler, R.J., et al. (2006) The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America. The Infectious Diseases Society of America.

  10. 10. Kalish, R.A., McHugh, G., Granquist, J., et al. (2001) Persistence of Immunoglobulin M or Immunoglobulin G Antibody Responses to Borrelia burgdorferi 10 - 20 Years after Active Lyme Disease. Clinical Infectious Diseases, 33, 780-785. http://dx.doi.org/10.1086/322669

  11. 11. Glatz, M., Fingerle, V., Wilske, B., Ambros-Rudolph, C., Kerl, H. and Müllegger, R.R. (2008) Immunoblot Analysis of the Seroreactivity to Recombinant Borrelia burgdorferi Sensu Lato Antigens, Including VlsE, in the Long-Term Course of Treated Patients with Erythema Migrans. Dermatology, 216, 93-103. http://dx.doi.org/10.1159/000111505

  12. 12. Vannier, E., Gewurz, B.E. and Krause, P.J. (2008) Human Babesiosis. Infectious Disease Clinics of North America, 22, 469-488. http://dx.doi.org/10.1016/j.idc.2008.03.010

  13. 13. Bean, C.A. and Fein, L.A. (2008) Beating Lyme, Understanding and Treating This Complex and Often Misdiagnosed Disease. AMACOM, New York.

  14. 14. Donta, S.T. (1997) Tetracycline Therapy for Chronic Lyme Disease. Clinical Infectious Diseases, 25, S52-S56. http://dx.doi.org/10.1086/516171

  15. 15. Wahlberg, P., Granlund, H., Nyman, D., Panelius, J. and Seppala, I. (1994) Treatment of Late Lyme Borreliosis. Journal of Infection, 29, 255-261. http://dx.doi.org/10.1016/S0163-4453(94)91105-3

  16. 16. Lebech, A.M., Hansen, K., Brandrup, F., et al. (2000) Diagnostic Value of PCR for Detection of Borrelia burgdorferi DNA in Clinical Specimens from Patients with Erythema Migrans and Lyme Neuroborreliosis. Molecular Diagnosis, 5, 139-150.

  17. 17. Cerar, T., Rusic-Sabljic, E., Glinsek, U., Zore, A. and Strle, F. (2008) Comparison of PCR Methods and Culture for the Detection of Borrelia spp. in Patients with Erythema Migrans. Clinical Microbiology and Infection, 14, 653-658. http://dx.doi.org/10.1111/j.1469-0691.2008.02013.x

  18. 18. Cameron, D.J. (2001) Lyme Disease Retreatment Study. A Double-Blind Placebo-Controlled Randomized Clinical Trial Evaluating the Efficacy of Oral Amoxicillin for Seropositive and Seronegative Lyme Disease. Enrollment Since 2001.

  19. 19. Ziska, M.H., Donta, S.T. and Demarest, F.C. (1996) Physician Preferences in the Diagnosis and Treatment of Lyme Disease in the United States. Infection, 24, 182-186. http://dx.doi.org/10.1007/BF01713336

  20. 20. Battaglia, H.R., Alvarez, G., Mercau, A., Fay, M. and Campodónico, M. (2000) Psychiatric Symptomatology Associated with Presumptive Lyme Disease: Clinical Evidence. J. Spirol. Tick Dis, 7, 22-25.

  21. 21. Fallon, B.A., Tager, F., Keilp, J., Weiss, N., Liebowitz, M.R., Fein, L. and Liegner, K. (1999) Repeated Antibiotic Treatment in Chronic Lyme Disease. J. Spiro Tick Dis, 6, 94-102.

  22. 22. Feder Jr., H.M. (2000) Differences Are Voiced by Two Lyme Camps at a Connecticut Public Hearing on Insurance Coverage of Lyme Disease. Pediatrics, 105, 855-857. http://dx.doi.org/10.1542/peds.105.4.855

  23. 23. Fallon, B.A. (2000) Chronic Lyme Disease Research Study. A Double-Blind Placebo-Controlled Randomized Clinical Trial Evaluating the Efficacy of Ten Weeks of iv. Ceftriaxone and Effects on Brain Imaging. Enrollment Since 2000.

  24. 24. Peña, C.A., Mathews, A.A., Siddiqi, N.H. and Strickland, G.T. (1999) Antibiotic Therapy for Lyme Disease in a Population-Based Cohort. Clinical Infectious Diseases, 29, 694-695. http://dx.doi.org/10.1086/598665

  25. 25. Eppes, S.C., Klein, J.D., Caputo, G. and Rose, C.D. (1994) Physician Beliefs, Attitudes and Approaches toward Lyme Disease in an Endemic Area. Clinical Pediatrics, 33, 130-134. http://dx.doi.org/10.1177/000992289403300301

  26. 26. Burrascano Jr., J.J. (2008) Diagnostic Hints and Treatment Guidelines for Lyme and Other Tick Borne Diseases.

  27. 27. Nowakowski, J., McKenna, D., Nadelman, R.B., et al. (2000) Failure of Treatment with Cephalexin for Lyme Disease. Archives of Family Medicine, 9, 563-567. http://dx.doi.org/10.1001/archfami.9.6.563

  28. 28. Nadelman, R.B. and Wormser, G.P. (1995) Erythema Migrans and Early Lyme Disease. The American Journal of Medicine, 98, S15-S24. http://dx.doi.org/10.1016/S0002-9343(99)80040-0

  29. 29. Stricker, R.B. and Lautin, A. (2003) The Lyme Wars: Time to Listen. Expert Opinion on Investigational Drugs, 12, 1609-1614. http://dx.doi.org/10.1517/13543784.12.10.1609

  30. 30. Asch, E.S., Bujak, D.I., Weiss, M., Peterson, M.G.E. and Weinstein, A. (1994) Lyme Disease: An Infectious and Postinfectious Syndrome. The Journal of Rheumatology, 21, 454-456.

  31. 31. Fallon, B.A. and Nields, J.A. (1994) Lyme Disease: A Neuropsychiatric Illness. The American Journal of Psychiatry, 151, 1571-1583. http://dx.doi.org/10.1176/ajp.151.11.1571

  32. 32. Logigian, E.L., Kaplan, R.F. and Steere, A.C. (1990) Chronic Neurologic Manifestations of Lyme Disease. The New England Journal of Medicine, 323, 1438-1444. http://dx.doi.org/10.1056/NEJM199011223232102

  33. 33. Bakken, J.S. and Dumler, S. (2008) Human Granulocytic Anaplasmosis. Infectious Disease Clinics of North America, 22, 433-448. http://dx.doi.org/10.1016/j.idc.2008.03.011

  34. 34. Steere, A.C., Dhar, A., Hernandez, J., et al. (2003) Systemic Symptoms without Erythema Migrans as the Presenting Picture of Early Lyme Disease. The American Journal of Medicine, 114, 58-62. http://dx.doi.org/10.1016/S0002-9343(02)01440-7

  35. 35. Fallon, B.A., Keilp, J.G., Corbera, K.M., Petkova, E., Britton, C.B., Dwyer, E., Slavov, I., Cheng, J., Dobkin, J., Nelson, D.R. and Sackeim, H.A. (2008) A Randomized, Placebo-Con- trolled Trial of Repeated IV Antibiotic Therapy for Lyme Encephalopathy. Neurology, 70, 992-1003. http://dx.doi.org/10.1212/01.WNL.0000284604.61160.2d

  36. 36. Klempner, M.S., Hu, L., Evans, J., Schmid, C.H., Johnson, G.M., Trevino, R.P., Norton, D., Levy, L., Wall, D., McCall, J., Kosinski, M. and Weinstein, A. (2001) Two Controlled Trials of Antibiotic Treatment in Patients with Persistent Symptoms and a History of Lyme Disease. The New England Journal of Medicine, 345, 85-92. http://dx.doi.org/10.1056/NEJM200107123450202

  37. 37. Klempner, M.S. (2002) Controlled Trials of Antibiotic Treatment in Patients with Post- Treatment Chronic Lyme Disease. Vector-Borne and Zoonotic Diseases, 2, 255-263. http://dx.doi.org/10.1089/153036602321653842

  38. 38. Fact Sheet (2006) Lyme Disease. Department of Health and Human Services, Division of Public Health Services.

  39. 39. Alban, P.S., Johnson, P.W. and Nelson, D.R. (2000) Serum-Starvation-Induced Changes in Protein Synthesis and Morphology of Borrelia burgdorferi. Microbiology, 146, 119-127. http://dx.doi.org/10.1099/00221287-146-1-119

  40. 40. Brorson, O. and Brorson, S.H. (1998) In Vitro Conversion of Borrelia burgdorferi to Cystic Forms in Spinal Fluid, and Transformation to Mobile Spirochetes by Incubation in BSK-H Medium. Infection, 26, 144-150. http://dx.doi.org/10.1007/BF02771839

  41. 41. Vermeersch, P., Resseler, S., Nackers, E. and Lagrou, K. (2009) The C6 Lyme Antibody Test Has Low Sensitivity for Antibody Detection in Cerebrospinal Fluid. Diagnostic Microbiology & Infectious Disease, 64, 347-349. http://dx.doi.org/10.1016/j.diagmicrobio.2009.03.013

  42. 42. Philipp, M.T., Marques, A.R., Fawcett, P.T., Dally, L.G. and Martin, D.S. (2003) C6 Test as an Indicator of Therapy Outcome for Patients with Localized or Disseminated Lyme Borreliosis. Journal of Clinical Microbiology, 41, 4955-4960. http://dx.doi.org/10.1128/JCM.41.11.4955-4960.2003

  43. 43. Wormser, G.P., Dattwyler, R.J., Shapiro, E.D., Halperin, J.J., Steere, A.C., Klempner, M.S., Krause, P.J., Bakken, J.S., Strle, F., Stanek, G., Bockenstedt, L., Fish, D., Dumler, J.S. and Nadelman, R.B. (2006) The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Disease Society of America. Clinical Infectious Diseases, 43, 1089-1134. http://cid.oxfordjournals.org/content/43/9/1089.long http://dx.doi.org/10.1086/508667

  44. 44. Oraze, M.J. and Charland, S.J. (1995) Lyme Disease Surveillance and Prevention Plan. Naval Surface Warfare Center, Naval Sea Systems Command, United States Navy, Indian Head, MD.

  45. 45. Wormser, G.P., Brisson, D., Liveris, D., et al. (2008) Borrelia burgdorferi Genotype Predicts the Capacity for Hematogenous Dissemination during Early Lyme Disease. The Journal of Infectious Diseases, 198, 1358-1364. http://dx.doi.org/10.1086/592279

  46. 46. Strle, F., Ruzic-Sabljic, E., Cimperman, J., et al. (2006) Comparison of Findings for Patients with Borreliagarinii and Borreliaafzelii Isolated from Cerebrospinal Fluid. Clinical Infectious Diseases, 43, 704-710. http://dx.doi.org/10.1086/506936

  47. 47. Wormser, G.P., Liveris, D., Hanincova, K., et al. (2008) Effect of Borrelia burgdorferi Genotype on the Sensitivity of C6 and 2-Tier Testing in North American Patients with Culture-Confirmed Lyme Disease. Clinical Infectious Diseases, 47, 910-914. http://dx.doi.org/10.1086/591529

  48. 48. Dattwyler, R.J., Halperin, J.J., Volkman, D.J. and Luft, B.J. (1988) Treatment of Late Lyme Borreliosis—Randomized Comparison of Ceftriaxone and Penicillin. Lancet, 331, 1191- 1194. http://dx.doi.org/10.1016/S0140-6736(88)92011-9

  49. 49. Wormser, G.P. (2006) The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America, by the Infectious Diseases Society of America.

  50. 50. Marques, A.R. (2010) Lyme Disease: A Review. Current Allergy and Asthma Reports, 10, 13-20.

  51. 51. Joseph, J. and Burrascano Jr., M.D. (2008) Advanced Topics in Lyme Disease, Diagnostic Hints and Treatment Guidelines for Lyme and Other Tick Borne Illnesses. 6th Edition, International Lyme and Associated Diseases Society.

  52. 52. Hanrahan, J.P., Benach, J.L., Coleman, J.L., Bosler, E.M., Grabau, J.C. and Morse, D.L. (1984) Epidemiologic Features of Lyme Disease in New York. Yale Journal of Biology and Medicine, 57, 643-650. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2590009/pdf/yjbm00100-0190.pdf

  53. 53. Daniels, T.J., Boccia, T.M., Varde, S., Marcus, J., Le, J., Bucher, D.J., Falco, R.C. and Schwartz, I. (1998) Geographic Risk of Lyme Disease and Human Granulocytic Ehrlichiosis in Southern New York State. Applied and Environmental Microbiology, 64, 4663-4669. http://aem.asm.org/cgi/content/full/64/12/4663?view=long&pmid=9835546

  54. 54. Pavia, C.S. (2003) Current and Novel Therapies for Lyme Disease. Expert Opinion on Investigational Drugs, 12, 1003-1016. http://dx.doi.org/10.1517/13543784.12.6.1003

  55. 55. Kaplan, R.F. and Steere, A.C. (1999) Successful Treatment of Lyme Encephalopathy with iv. Ceftriaxone. The Journal of Infectious Diseases, 180, 377-383.

  56. 56. Schoen, R.T., Aversa, J.M., Rahn, D.W. and Steere, A.C. (1991) Treatment of Refractory Chronic Lyme Arthritis with Arthroscopic Synovectomy. Arthritis & Rheumatology, 34, 1056-1060. http://dx.doi.org/10.1002/art.1780340817

  57. 57. Masters, E.J., Grigery, C.N. and Masters, R.W. (2008) STARI, or Masters Disease: Lone Star tick-Vectored Lyme-Like Illness. Infectious Disease Clinics of North America, 22, 361-376. http://dx.doi.org/10.1016/j.idc.2007.12.010

  58. 58. Ball, R., Shadomy, S.V., Meyer, A., et al. (2009) HLA Type and Immune Response to Borrelia burgdorferi Outer Surface Protein A in People in Whom Arthritis Developed after Lyme Disease Vaccination. Arthritis & Rheumatology, 60, 1179-1186. http://dx.doi.org/10.1002/art.24418

  59. 59. Steere, A.C. (2006) Lyme Borreliosis in 2005, 30 Years after Initial Observations in Lyme Connecticut. Wiener Klinische Wochenschrift, 118, 625-633. http://dx.doi.org/10.1007/s00508-006-0687-x

  60. 60. Trevejo, R.T., Krause, P.J., Sikand, V.K., Schriefer, M.E., Ryan, R., Lepore, T., et al. (1999) Evaluation of Two-Test Serodiagnostic Method for Early Lyme Disease in Clinical Practice. The Journal of Infectious Diseases, 179, 931-938. http://dx.doi.org/10.1086/314663

  61. 61. Von Lackum, K., Babb, K., Riley, S.P., Wattier, R.L., Bykowski, T. and Stevenson, B. (2006) Functionality of Borrelia burgdorferi LuxS: The Lyme Disease Spirochete Produces and Responds to the Pheromone Autoinducer-2 and Lacks a Complete Activated-Methyl Cycle. International Journal of Medical Microbiology, 296, 92-102. http://dx.doi.org/10.1016/j.ijmm.2005.12.011

  62. 62. Aberer, E. (2007) Lyme Borreliosis—An Update. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 5, 406-414. http://dx.doi.org/10.1111/j.1610-0387.2007.06285.x

  63. 63. Acha, P.N. and Szyfres, B. (Pan American Health Organization [PAHO]) (2003) Zoonoses and Communicable Diseases Common to Man and Animals. Volume 1. Bacterioses and Mycoses. 3rd Edition, Scientific and Technical Publication No. 580. Lyme Disease, PAHO, Washington DC, 179-184.

  64. 64. Ekerfelt, C., Andersson, M., Olausson, A., et al. (2007) Mercury Exposure as a Model for Deviation of Cytokine Responses in Experimental Lyme Arthritis: HgCl2 Treatment Decreases T Helper Cell Type 1-Like Responses and Arthritis Severity but Delays Eradication of Borrelia burgdorferi in C3H/HeN Mice. Clinical & Experimental Immunology, 150, 189- 197. http://dx.doi.org/10.1111/j.1365-2249.2007.03474.x

  65. 65. Miller, J.C., Ma, Y., Bian, J., et al. (2008) A Critical Role for Type I IFN in Arthritis Development Following Borrelia burgdorferi Infection of Mice. The Journal of Immunology, 181, 8492-8503. http://dx.doi.org/10.4049/jimmunol.181.12.8492

  66. 66. Lagal, V., Postic, D., Rubic-Sabljic, E. and Baranton, G. (2003) Genetic Diversity among Borrelia Strains Determined by Single-Strand Conformation Polymorphism Analysis of the ospC Gene and Its Association with Invasiveness. Journal of Clinical Microbiology, 41, 5059-5065. http://dx.doi.org/10.1128/JCM.41.11.5059-5065.2003

  67. 67. Zore, A., Ruzic-Sabljic, E., Maraspin, V., et al. (2002) Sensitivity of Culture and Polymerase Chain Reaction for the Etiologic Diagnosis of Erythema Migrans. Wiener Klinische Wochenschrift, 114, 606-609.

  68. 68. Fritz, C.L. and Kjemtrup, A.M. (2003) Lyme Borreliosis. Journal of the American Veterinary Medical Association, 223, 1261-1270. http://dx.doi.org/10.2460/javma.2003.223.1261

  69. 69. Stafford, K.C. (2004) Tick Management Handbook. The Connecticut Agricultural Experiment Station, Connecticut General Assembly, New Haven.

  70. 70. Walker, E.D. and Stachecki, J.A. (2008) Livestock Pest Management. A Training Manual for Commercial Pesticide Applicators, 54.

  71. 71. Bacon, R.M., Kugeler, K.J. and Mead, P.S. (2008) Surveillance for Lyme Disease—United States, 1992-2006. MMWR Surveill Summ, 57, 1-9.

  72. 72. Piesman, J., Mather, T.N., Sinsky, R.J. and Spielman, A. (1987) Duration of Tick Attachment and Borrelia burgdorferi Transmission. Journal of Clinical Microbiology, 25, 557-558.

  73. 73. Nadelman, R.B., Nowakowski, J., Forseter, G., et al. (1996) The Clinical Spectrum of Early Lyme Borreliosis in Patients with Culture-Confirmed Erythema Migrans. The American Journal of Medicine, 100, 502-508. http://dx.doi.org/10.1016/S0002-9343(95)99915-9

  74. 74. Strle, F., Nadelman, R.B., Cimperman, J., et al. (1999) Comparison of Culture-Confirmed Erythema Migrans Caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia. Annals of Internal Medicine, 130, 32-36. http://dx.doi.org/10.7326/0003-4819-130-1-199901050-00006

  75. 75. Walker, E.D. and Stachecki, J.A. (2008) Livestock Pest Management. A Training Manual for Commercial Pesticide Applicators. New York.

List of Abbreviations

LD: Lyme Disease

B. burgdorferi: Borrelia burgdorferi

CSF: Cerebral spinal Fluid

CNS: Central Nervous System

HGA: Human granulocytic Anaplasmosis

ILADS: International Lyme Associated Disease Society

Submit or recommend next manuscript to SCIRP and we will provide best service for you:

Accepting pre-submission inquiries through Email, Facebook, LinkedIn, Twitter, etc.

A wide selection of journals (inclusive of 9 subjects, more than 200 journals)

Providing 24-hour high-quality service

User-friendly online submission system

Fair and swift peer-review system

Efficient typesetting and proofreading procedure

Display of the result of downloads and visits, as well as the number of cited articles

Maximum dissemination of your research work

Submit your manuscript at: http://papersubmission.scirp.org/